APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pneumonia Therapeutics Market Analysis and Forecast 2026-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchPneumonia Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Pneumonia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pneumonia Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pneumonia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pneumonia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pneumonia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pneumonia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pneumonia Therapeutics include Novartis, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Tetraphase Pharmaceuticals, Merck Sharp & Dohme and Biotest, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pneumonia Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pneumonia Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Pneumonia Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumonia Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumonia Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pneumonia Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Pneumonia Therapeutics Segment by Company

Novartis

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Tetraphase Pharmaceuticals

Merck Sharp & Dohme

Biotest

Pneumonia Therapeutics Segment by Type

Vaccines

Anti-Infectives

Oxygen Therapy

Pneumonia Therapeutics Segment by Application

Clinic

Hospital

Medical Center

Other

Pneumonia Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pneumonia Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pneumonia Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumonia Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumonia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vaccines Major Player Table 3. Anti-Infectives Major Player Table 4. Oxygen Therapy Major Player Table 5. Global Pneumonia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Clinic Major Player Table 7. Hospital Major Player Table 8. Medical Center Major Player Table 9. Other Major Player Table 10. Pneumonia Therapeutics Industry Trends Table 11. Pneumonia Therapeutics Industry Drivers Table 12. Pneumonia Therapeutics Industry Opportunities and Challenges Table 13. Pneumonia Therapeutics Industry Restraints Table 14. Global Pneumonia Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Pneumonia Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Pneumonia Therapeutics Market Share by Region (2021-2026) Table 17. Global Pneumonia Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Pneumonia Therapeutics Market Share by Region (2027-2032) Table 19. Global Pneumonia Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Pneumonia Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Pneumonia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Pneumonia Therapeutics Key Players Headquarters & Area Served Table 23. Global Pneumonia Therapeutics Players, Product Type & Application Table 24. Global Pneumonia Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Pneumonia Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Pneumonia Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Pneumonia Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Pneumonia Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Pneumonia Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Pneumonia Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Pneumonia Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Novartis Company Information Table 38. Novartis Business Overview Table 39. Novartis Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Novartis Pneumonia Therapeutics Product Portfolio Table 41. Novartis Recent Development Table 42. Pfizer Company Information Table 43. Pfizer Business Overview Table 44. Pfizer Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Pfizer Pneumonia Therapeutics Product Portfolio Table 46. Pfizer Recent Development Table 47. GlaxoSmithKline Company Information Table 48. GlaxoSmithKline Business Overview Table 49. GlaxoSmithKline Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. GlaxoSmithKline Pneumonia Therapeutics Product Portfolio Table 51. GlaxoSmithKline Recent Development Table 52. Bayer Company Information Table 53. Bayer Business Overview Table 54. Bayer Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Bayer Pneumonia Therapeutics Product Portfolio Table 56. Bayer Recent Development Table 57. AstraZeneca Company Information Table 58. AstraZeneca Business Overview Table 59. AstraZeneca Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. AstraZeneca Pneumonia Therapeutics Product Portfolio Table 61. AstraZeneca Recent Development Table 62. Tetraphase Pharmaceuticals Company Information Table 63. Tetraphase Pharmaceuticals Business Overview Table 64. Tetraphase Pharmaceuticals Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Tetraphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio Table 66. Tetraphase Pharmaceuticals Recent Development Table 67. Merck Sharp & Dohme Company Information Table 68. Merck Sharp & Dohme Business Overview Table 69. Merck Sharp & Dohme Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio Table 71. Merck Sharp & Dohme Recent Development Table 72. Biotest Company Information Table 73. Biotest Business Overview Table 74. Biotest Pneumonia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biotest Pneumonia Therapeutics Product Portfolio Table 76. Biotest Recent Development Table 77. North America Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Pneumonia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Pneumonia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Pneumonia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Pneumonia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 91. China Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 92. China Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 93. China Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 94. China Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Pneumonia Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Pneumonia Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Pneumonia Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Pneumonia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Pneumonia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Pneumonia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Pneumonia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Pneumonia Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Pneumonia Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Pneumonia Therapeutics Image Figure 2. Global Pneumonia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vaccines Image Figure 5. Anti-Infectives Image Figure 6. Oxygen Therapy Image Figure 7. Global Pneumonia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pneumonia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Clinic Image Figure 10. Hospital Image Figure 11. Medical Center Image Figure 12. Other Image Figure 13. Global Pneumonia Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Pneumonia Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Pneumonia Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Pneumonia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Pneumonia Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pneumonia Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pneumonia Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Pneumonia Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pneumonia Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Pneumonia Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Pneumonia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Pneumonia Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Pneumonia Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Pneumonia Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Pneumonia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Pneumonia Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Pneumonia Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Pneumonia Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Pneumonia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Pneumonia Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Pneumonia Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Pneumonia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Pneumonia Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Pneumonia Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Pneumonia Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Pneumonia Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Pneumonia Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Pneumonia Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Pneumonia Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Pneumonia Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Anti-Infectives
  • Oxygen Therapy
Applications
  • Clinic
  • Hospital
  • Medical Center
  • Other
Companies covered
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Tetraphase Pharmaceuticals
  • Merck Sharp & Dohme
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pneumonia Therapeutics Market by Type
  3. 1.2.1 Global Pneumonia Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccines
  5. 1.2.3 Anti-Infectives
  6. 1.2.4 Oxygen Therapy
  7. 1.3 Pneumonia Therapeutics Market by Application
  8. 1.3.1 Global Pneumonia Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinic
  10. 1.3.3 Hospital
  11. 1.3.4 Medical Center
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Pneumonia Therapeutics Market Dynamics
  1. 2.1 Pneumonia Therapeutics Industry Trends
  2. 2.2 Pneumonia Therapeutics Industry Drivers
  3. 2.3 Pneumonia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Pneumonia Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pneumonia Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Pneumonia Therapeutics Growth Trends by Region
  3. 3.2.1 Global Pneumonia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pneumonia Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Pneumonia Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pneumonia Therapeutics Revenue by Players
  2. 4.1.1 Global Pneumonia Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Pneumonia Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pneumonia Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pneumonia Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pneumonia Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Pneumonia Therapeutics Players, Product Type & Application
  8. 4.5 Global Pneumonia Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pneumonia Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Pneumonia Therapeutics Tier 1, Tier 2, and Tier 3
5 Pneumonia Therapeutics Market Size by Type
  1. 5.1 Global Pneumonia Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Pneumonia Therapeutics Revenue Market Share by Type (2021-2032)
6 Pneumonia Therapeutics Market Size by Application
  1. 6.1 Global Pneumonia Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pneumonia Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Pneumonia Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Pneumonia Therapeutics Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Pneumonia Therapeutics Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GlaxoSmithKline
  14. 7.3.1 GlaxoSmithKline Company Information
  15. 7.3.2 GlaxoSmithKline Business Overview
  16. 7.3.3 GlaxoSmithKline Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Pneumonia Therapeutics Product Portfolio
  18. 7.3.5 GlaxoSmithKline Recent Developments
  19. 7.4 Bayer
  20. 7.4.1 Bayer Company Information
  21. 7.4.2 Bayer Business Overview
  22. 7.4.3 Bayer Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bayer Pneumonia Therapeutics Product Portfolio
  24. 7.4.5 Bayer Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Pneumonia Therapeutics Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Tetraphase Pharmaceuticals
  32. 7.6.1 Tetraphase Pharmaceuticals Company Information
  33. 7.6.2 Tetraphase Pharmaceuticals Business Overview
  34. 7.6.3 Tetraphase Pharmaceuticals Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Tetraphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio
  36. 7.6.5 Tetraphase Pharmaceuticals Recent Developments
  37. 7.7 Merck Sharp & Dohme
  38. 7.7.1 Merck Sharp & Dohme Company Information
  39. 7.7.2 Merck Sharp & Dohme Business Overview
  40. 7.7.3 Merck Sharp & Dohme Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio
  42. 7.7.5 Merck Sharp & Dohme Recent Developments
  43. 7.8 Biotest
  44. 7.8.1 Biotest Company Information
  45. 7.8.2 Biotest Business Overview
  46. 7.8.3 Biotest Pneumonia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biotest Pneumonia Therapeutics Product Portfolio
  48. 7.8.5 Biotest Recent Developments
8 North America
  1. 8.1 North America Pneumonia Therapeutics Revenue (2021-2032)
  2. 8.2 North America Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Pneumonia Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Pneumonia Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Pneumonia Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Pneumonia Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Pneumonia Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Pneumonia Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Pneumonia Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Pneumonia Therapeutics Revenue by Country
  11. 8.6.1 North America Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pneumonia Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Pneumonia Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Pneumonia Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pneumonia Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pneumonia Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Pneumonia Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pneumonia Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pneumonia Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pneumonia Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Pneumonia Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pneumonia Therapeutics Revenue by Country
  11. 9.6.1 Europe Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pneumonia Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pneumonia Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Pneumonia Therapeutics Revenue (2021-2032)
  2. 10.2 China Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Pneumonia Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Pneumonia Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Pneumonia Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Pneumonia Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Pneumonia Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Pneumonia Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Pneumonia Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pneumonia Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pneumonia Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pneumonia Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Pneumonia Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pneumonia Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pneumonia Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pneumonia Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Pneumonia Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pneumonia Therapeutics Revenue by Country
  11. 11.6.1 Asia Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pneumonia Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pneumonia Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pneumonia Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Pneumonia Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pneumonia Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pneumonia Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pneumonia Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pneumonia Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pneumonia Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pneumonia Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pneumonia Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pneumonia Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Pneumonia Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pneumonia Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pneumonia Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst